Abstract:Abstract Background: Age is the largest risk factor for breast cancer development. Faster biological aging, particularly in breast tissue, may predispose women to higher risk of developing breast cancer. Recently, a set of promising biomarkers of aging, called “epigenetic clocks” (also referred to as “epigenetic age”) have been developed to estimate aging rates in tissues and cells. Using one of the original epigenetic clocks based on DNA methylation patterns, we previously demonstrated that normal breast tissue from luminal breast cancer patients exhibited accelerated aging compared to patients without breast cancer. Here we test whether incorporation of nearly a dozen epigenetic clocks, each capturing slightly different biological aging phenomena, can consistently distinguish normal breast tissue from cancer patients versus healthy controls. We also examined concordance between epigenetic age assessment from paired breast tissue and peripheral blood mononuclear cells. Methods: We examined 282 specimens including DNA from 94 normal breast tissues (41 from patients with breast cancer, and 53 from non-cancer controls) and 188 blood samples (97 from breast cancer, and 91 from controls). DNA methylation was assessed via the Illumina HumanMethylation450k and HumanMethylationEPIC BeadChip for both tissue and blood samples, and 11 epigenetic clocks were calculated following published methods. Associations of these clocks with breast cancer were examined using logistic regression models and Receiver Operating Characteristics (ROC) curves to determine predictive power in distinguishing samples from cancer patients versus healthy controls. Results: After accounting for chronological age, we observed increases in most epigenetic clocks for cancer patients compared to normal samples from controls, which indicates accelerated epigenetic aging (e.g., Zhang clock in tissue, 0.55 vs. -0.42; in blood, 0.10 vs. -0.20, all P<0.05). When including age, Zhang clock showed the best predictive power of breast cancer in tissues (Area Under The Curve [AUC] =0.79, 95% Confidence Interval [CI]: 0.69, 0.87) and including all clocks further improved the predictive power (AUC=0.89, 95% CI: 0.83, 0.95). However, all clocks exhibited moderate predictive powers in blood (all AUC<0.7), even when combining them together (AUC=0.70, 95% CI: 0.62, 0.77). In 80 participants with both tissue and blood samples, we observed highest concordance for Hannum clock (bicor=0.43) and lowest concordance for Zhang clock (bicor =-0.19). Conclusions: Epigenetic aging-based biomarkers distinguish non-tumor breast tissues of patients with breast cancer from breast tissues of healthy controls. These findings raise the possibility that epigenetic markers assessed on needle biopsies of the breast might identify individuals at risk for developing breast cancer. Citation Format: Erin Hofstatter, Morgan Levine, Zuyun Liu, Tess O'Meara, Disha Dalela, Lajos Pusztai. Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer compared to women without cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-09-02.

Blood Immunosenescence Signatures Reflecting Age, Frailty and Tumor Immune Infiltrate in Patients with Early Luminal Breast Cancer

Age-related remodelling of the blood immunological portrait and the local tumor immune response in patients with luminal breast cancer

Biological ageing and frailty markers in breast cancer patients

Blood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapy

Abstract P2-09-02: Evidence of Accelerated Epigenetic Aging of Breast Tissues in Patients with Breast Cancer Compared to Women Without Cancer

Evaluating the physiological reserves of older patients with cancer: The value of potential biomarkers of aging?

Dissecting the immune infiltrate of primary luminal B‐like breast carcinomas in relation to age

Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty

Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survival

Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: correlation with chronological age but not with fitness/frailty status

Blood-based biomarkers for early frailty are sex-specific: validation of a combined in silico prediction and data-driven approach

Blood-based biomarkers of frailty in solid tumors: a systematic review

The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy

Circulating Angiogenic and Senescent T Lymphocytes in Ageing and Frailty

Combination of the biomarkers for aging and cancer? - Challenges and current status

Determining the relationship of p16INK4a and additional molecular markers of aging with clinical frailty in hematologic malignancy

Exploring Early Detection of Frailty Syndrome in Older Adults: Evaluation of Oxi-Immune Markers, Clinical Parameters and Modifiable Risk Factors

Markers of aging: Unsupervised integrated analyses of the human plasma proteome

sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence

In-depth human immune cellular profiling from newborn to frail

Transcriptomic markers of biological aging in breast cancer survivors: a longitudinal study